Cell‐free fetal DNA screening in the USA: a cost analysis of screening strategies

ABSTRACT Objectives To determine whether implementation of primary cell‐free fetal DNA (cffDNA) screening would be cost‐effective in the USA and to evaluate potential lower‐cost alternatives. Methods Three strategies to screen for trisomy 21 were evaluated using decision tree analysis: 1) a primary...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ultrasound in obstetrics & gynecology 2015-01, Vol.45 (1), p.74-83
Hauptverfasser:	Evans, M. I., Sonek, J. D., Hallahan, T. W., Krantz, D. A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult aneuploidy serum markers Cell-Free System cell‐free fetal DNA Chorionic Gonadotropin, beta Subunit, Human - blood cost analysis Cost-Benefit Analysis Costs and Cost Analysis Deoxyribonucleic acid DNA DNA - blood Down syndrome Down syndrome screening Female Gestational Age Humans Maternal Age nasal bone nuchal translucency Nuchal Translucency Measurement - economics Patients Pregnancy Pregnancy Trimester, First Pregnancy-Associated Plasma Protein-A - metabolism Prenatal Diagnosis - economics Trisomy - diagnosis Ultrasonography, Prenatal - economics United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACT Objectives To determine whether implementation of primary cell‐free fetal DNA (cffDNA) screening would be cost‐effective in the USA and to evaluate potential lower‐cost alternatives. Methods Three strategies to screen for trisomy 21 were evaluated using decision tree analysis: 1) a primary strategy in which cffDNA screening was offered to all patients, 2) a contingent strategy in which cffDNA screening was offered only to patients who were high risk on traditional first‐trimester screening and 3) a hybrid strategy in which cffDNA screening was offered to all patients ≥ 35 years of age and only to patients
ISSN:	0960-7692 1469-0705
DOI:	10.1002/uog.14693